Experts pushing remdesivir (over hydroxychloroquine, which costs much less) have financial ties to Gilead, the company that makes it

[Mark Crispin Miller]

"When it comes to money, we checked financial ties among experts on the government panel devising coronavirus treatment guidelines— which had the effect of dialing back hydroxychloroquine use and giving an edge to remdesivir.

"We found that of 11 members reporting links to a drug company, nine of them named relationships to remdesivir’s maker Gilead. Seven more, including two of the committee’s leaders, have ties to Gilead beyond the 11 months they had to disclose. [Yellow in graphic below] Two were on Gilead’s advisory board. Others were paid consultants or received research support and honoraria. Nobody reported ties to hydroxychloroquine which is now made by numerous generic manufacturers and is so cheap, analysts say even a spike in sales would not be a financial driver for the companies."

Hydroxychloroquine

BY FULL MEASURE STAFF SUNDAY, MAY 17TH 2020

http://fullmeasure.news/news/cover-story/hydroxychloroquine

Drug Battle

 

Drug Battle

 

 

If you’ve watched the news lately, you might be under the impression that a medicine President Trump touted as a possible game changer against coronavirus— has been debunked and discredited. Two divergent views of the drug, hydroxychloroquine, have emerged: the negative one widely reported in the press and another side you’ve probably heard less about. Never has a discussion about choices of medicine been so laced with political overtones. Today, how politics, money and medicine intersect with coronavirus.

Click on the link for the rest.